Eleven Biotherapeutics, Inc. EBIO
Set alert
At close · Jun 28
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
News
8 years ago businesswire.com
Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of…
8 years ago businesswire.com
Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics…
9 years ago businesswire.com
Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
9 years ago businesswire.com
Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
9 years ago businesswire.com
Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
9 years ago businesswire.com
Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late stage clinical oncology company advancing a broad pipeline of novel product candidates based on a Targeting…
10 years ago businesswire.com
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
CAMBRIDGE, Mass. & TORONTO--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today announced that the two companies and the shareholders of Viventia entered into a…
11 years ago businesswire.com
Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
11 years ago businesswire.com
Eleven Biotherapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
11 years ago businesswire.com
Eleven Biotherapeutics Announces Top-Line Results from Pivotal Phase 3 Study of EBI-005 in Patients with Moderate to Severe Dry Eye Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
11 years ago businesswire.com
Eleven Biotherapeutics to Report First Quarter 2015 Financial Results on April 30, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
11 years ago businesswire.com
Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on March 4, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today…
11 years ago businesswire.com
Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
11 years ago businesswire.com
Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
12 years ago businesswire.com
Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
12 years ago businesswire.com
Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
12 years ago businesswire.com
Eleven Biotherapeutics to Report First Quarter 2014 Financial Results on May 15, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…